Clinical Trial Update: Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating phenotyping of idiopathic pelvic pain with real-time uterine imaging in combination with Relugolix has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pelvic Pain

Drugs mentioned

• Relugolix (Relugolix)

Snippet

Sponsor: Endeavor Health | Conditions: Pelvic Pain | Phase 2 | Status: WITHDRAWN